Morgan Stanley Imara Inc. Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$3.73 - $5.2 $16,840 - $23,478	-4,515 Reduced 7.37%	56,748 $232,000
Q3 2022 Nov 14, 2022	SELL	$1.11 - $2.42 $34,222 - $74,611	-30,831 Reduced 33.48%	61,263 $140,000
Q2 2022 Oct 27, 2022	SELL	$0.99 - $1.87 $9,741 - $18,400	-9,840 Reduced 9.65%	92,094 $112,000
Q2 2022 Aug 15, 2022	SELL	$0.99 - $1.87 $9,741 - $18,400	-9,840 Reduced 9.65%	92,094 $112,000
Q1 2022 Oct 27, 2022	BUY	$1.15 - $2.41 $11,316 - $23,714	9,840 Added 10.68%	101,934 $191,000
Q1 2022 May 13, 2022	SELL	$1.15 - $2.41 $263,174 - $551,521	-228,847 Reduced 69.18%	101,934 $191,000
Q4 2021 Feb 14, 2022	BUY	$2.25 - $4.05 $90,299 - $162,538	40,133 Added 13.81%	330,781 $744,000
Q3 2021 Nov 15, 2021	BUY	$4.08 - $7.83 $1.19 Million - $2.28 Million	290,648 New	290,648 $1.19 Million

104K

170K

Ticker IMRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,287,300
Market Cap $552M
Description
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develop...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.